Literature DB >> 11168387

CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains.

S Mukhopadhyay1, A C Howlett.   

Abstract

The CB1 cannabinoid receptor in N18TG2 neuroblastoma cells inhibits adenylate cyclase, and this response can be mimicked by a peptide corresponding to the juxtamembrane C-terminal domain (CB(1)401-417). Guanosine 5'-O-(3-thio)triphosphate binding to G proteins can be stimulated by both peptide CB(1)401-417 and peptides corresponding to the third intracellular loop [Howlett, A.C., Song, C., Berglund, B.A., Wilken, G.H. & Pigg, J.J. (1998) Mol. Pharmacol. 53, 504-510; Mukhopadhyay, S., Cowsik, S.M., Welsh, W.J. & Howlett, A.C. (1999) Biochemistry 38, 3447-3455]. In Chaps-solubilized N18TG2 membranes, the CB1 receptor coimmunoprecipitated with all three Gi subtypes. Pertussis toxin significantly reduced the CB(1) receptor-G alpha(i) association and attenuated the CB(1)401-417-induced inhibition of adenylate cyclase. CB(1)401-417 significantly reduced the CB(1) receptor association with G alpha(i3), but not with G alpha(i1) or G alpha(i2). In contrast, third intracellular loop peptides significantly reduced the CB(1) receptor association with G alpha(i1) and G alpha(i2), but not G alpha(i3). These interactions are specific for the CB(1) receptor because a peptide corresponding to the juxtamembrane C-terminal domain of the CB(2) receptor failed to compete for the association of the CB1 receptor with any of the Gi alpha subtypes, and was not able to activate Gi proteins to inhibit adenylate cyclase. These studies indicate that different domains of the CB(1) receptor direct the interaction with specific G protein subtypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168387     DOI: 10.1046/j.1432-1327.2001.01810.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  26 in total

1.  Cannabinoid receptor-G protein interactions: G(alphai1)-bound structures of IC3 and a mutant with altered G protein specificity.

Authors:  Amy L Ulfers; Jonathan L McMurry; Alexander Miller; Ligong Wang; Debra A Kendall; Dale F Mierke
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

Review 2.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.

Authors:  Lina Yao; Krista McFarland; Peidong Fan; Zhan Jiang; Takashi Ueda; Ivan Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

4.  Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling.

Authors:  Sergio Oddi; Enrico Dainese; Simone Sandiford; Filomena Fezza; Mirko Lanuti; Valerio Chiurchiù; Antonio Totaro; Giuseppina Catanzaro; Daniela Barcaroli; Vincenzo De Laurenzi; Diego Centonze; Somnath Mukhopadhyay; Jana Selent; Allyn C Howlett; Mauro Maccarrone
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

5.  Hydrophobic residues in helix 8 of cannabinoid receptor 1 are critical for structural and functional properties.

Authors:  Kwang H Ahn; Akiko Nishiyama; Dale F Mierke; Debra A Kendall
Journal:  Biochemistry       Date:  2010-01-26       Impact factor: 3.162

6.  CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Authors:  Gemma L Baillie; James G Horswill; Sharon Anavi-Goffer; Patricia H Reggio; Daniele Bolognini; Mary E Abood; Sean McAllister; Phillip G Strange; Gary J Stephens; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2012-11-15       Impact factor: 4.436

7.  CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.

Authors:  Khalil Eldeeb; Sandra Leone-Kabler; Allyn C Howlett
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

8.  Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites.

Authors:  Lawrence C Blume; Theresa Patten; Khalil Eldeeb; Sandra Leone-Kabler; Alexander A Ilyasov; Bradley M Keegan; Jeremy E O'Neal; Caroline E Bass; Roy R Hantgan; W Todd Lowther; Dana E Selley; A Llyn C Howlett
Journal:  Mol Pharmacol       Date:  2016-11-28       Impact factor: 4.436

9.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

Review 10.  The pharmacology of the cannabinoid system--a question of efficacy and selectivity.

Authors:  Christopher J Fowler
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.